457 related articles for article (PubMed ID: 32588337)
41. Patients experiences with multiple sclerosis disease-modifying therapies in daily life - a qualitative interview study.
Sippel A; Riemann-Lorenz K; Scheiderbauer J; Kleiter I; Morrison R; Kofahl C; Heesen C
BMC Health Serv Res; 2021 Oct; 21(1):1141. PubMed ID: 34686166
[TBL] [Abstract][Full Text] [Related]
42. An international discrete choice experiment assessing patients' preferences for disease-modifying therapy attributes in multiple sclerosis.
Bauer B; Brockmeier B; Devonshire V; Charbonne A; Wach D; Hendin B
Neurodegener Dis Manag; 2020 Dec; 10(6):369-382. PubMed ID: 32873160
[No Abstract] [Full Text] [Related]
43. Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis.
Neuberger EE; Abbass IM; Jones E; Engmann NJ
Neurol Ther; 2021 Jun; 10(1):183-196. PubMed ID: 33244713
[TBL] [Abstract][Full Text] [Related]
44. Pregnancy and multiple sclerosis in the DMT era: A cohort study in Western Austria.
Bsteh G; Algrang L; Hegen H; Auer M; Wurth S; Di Pauli F; Deisenhammer F; Berger T
Mult Scler; 2020 Jan; 26(1):69-78. PubMed ID: 30507345
[TBL] [Abstract][Full Text] [Related]
45. No evidence of disease activity-3 (NEDA-3) status in patients with relapsing remitting multiple sclerosis: Evidence from Saudi cohort receiving mainly Interferon.
Zafar A; AlShamrani FJG
Mult Scler Relat Disord; 2021 Jun; 51():102875. PubMed ID: 33691260
[TBL] [Abstract][Full Text] [Related]
46. Factors influencing patients' willingness-to-pay for disease-modifying therapies for multiple sclerosis.
Poudel N; Banjara B; Kamau S; Frost N; Ngorsuraches S
Mult Scler Relat Disord; 2021 Feb; 48():102720. PubMed ID: 33429304
[TBL] [Abstract][Full Text] [Related]
47. Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 years.
Oh J; Achiron A; Celius EG; Chambers C; Derwenskus J; Devonshire V; Hellwig K; Hutton GJ; McCombe P; Moore M; Rog D; Schneider JR; Simm RF; Sousa L; Vincent SG; Chung L; Daizadeh N; Mitchell C; Compston DAS;
Mult Scler Relat Disord; 2020 Aug; 43():102146. PubMed ID: 32498033
[TBL] [Abstract][Full Text] [Related]
48. How do women trade-off benefits and risks in chemotherapy treatment decisions based on gene expression profiling for early-stage breast cancer? A discrete choice experiment.
Marshall DA; Deal K; Bombard Y; Leighl N; MacDonald KV; Trudeau M
BMJ Open; 2016 Jun; 6(6):e010981. PubMed ID: 27256091
[TBL] [Abstract][Full Text] [Related]
49. Exploring women's preferences for birth settings in England: A discrete choice experiment.
Fletcher BR; Rowe R; Hollowell J; Scanlon M; Hinton L; Rivero-Arias O
PLoS One; 2019; 14(4):e0215098. PubMed ID: 30973919
[TBL] [Abstract][Full Text] [Related]
50. A Systematic Review of Discrete-Choice Experiments and Conjoint Analysis Studies in People with Multiple Sclerosis.
Webb EJD; Meads D; Eskyte I; King N; Dracup N; Chataway J; Ford HL; Marti J; Pavitt SH; Schmierer K; Manzano A
Patient; 2018 Aug; 11(4):391-402. PubMed ID: 29313265
[TBL] [Abstract][Full Text] [Related]
51. Evaluation of diagnosis and treatment practices of Brazilian neurologists among patients with multiple sclerosis.
Marin CE; Callegaro D; Lana-Peixoto MA; Fernández O; Gomes Neto AP; Vasconcelos CCF; d'Almeida JAC; Gonçalves MVM; Mendes MF; Parolin MKF; Nascimento O; Gama PDD; Dias-Carneiro RPC; Dias RM; Damasceno A; Becker J
Arq Neuropsiquiatr; 2021 Jul; 79(7):598-606. PubMed ID: 34468497
[TBL] [Abstract][Full Text] [Related]
52. Peginterferon beta-1a versus other self-injectable disease-modifying therapies in the treatment of relapsing-remitting multiple sclerosis in Scotland: a cost-effectiveness analysis.
Hernandez L; Guo S; Toro-Diaz H; Carroll S; Syed Farooq SF
J Med Econ; 2017 Mar; 20(3):228-238. PubMed ID: 27730845
[TBL] [Abstract][Full Text] [Related]
53. A discrete choice experiment to determine patient preferences for injection devices in multiple sclerosis.
Shingler SL; Swinburn P; Ali S; Perard R; Lloyd AJ
J Med Econ; 2013 Aug; 16(8):1036-42. PubMed ID: 23730944
[TBL] [Abstract][Full Text] [Related]
54. Optimization and stratification of multiple sclerosis treatment in fast developing economic countries: a perspective from Qatar.
Deleu D; Mesraoua B; El Khider H; Canibano B; Melikyan G; Al Hail H; Mhjob N; Bhagat A; Ibrahim F; Hanssens Y
Curr Med Res Opin; 2017 Mar; 33(3):439-458. PubMed ID: 27892723
[TBL] [Abstract][Full Text] [Related]
55. Assessing Pharmacists' Preferences towards Efficacy Attributes of Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis.
Martínez-López I; Maurino J; Sanmartín-Fenollera P; Ontañon-Nasarre A; Santiago-Pérez A; Moya-Carmona I; García-Collado CG; Fernández-Del Olmo R; García-Arcelay E; Sarmiento M; Carreño Á; Pérez-Encinas M
Pharmacy (Basel); 2020 Apr; 8(2):. PubMed ID: 32272683
[No Abstract] [Full Text] [Related]
56. Disease-Modifying Therapies for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis.
Zimmermann M; Brouwer E; Tice JA; Seidner M; Loos AM; Liu S; Chapman RH; Kumar V; Carlson JJ
CNS Drugs; 2018 Dec; 32(12):1145-1157. PubMed ID: 30141001
[TBL] [Abstract][Full Text] [Related]
57. Established disease-modifying treatments in relapsing-remitting multiple sclerosis.
Oh J; O'Connor PW
Curr Opin Neurol; 2015 Jun; 28(3):220-9. PubMed ID: 25923124
[TBL] [Abstract][Full Text] [Related]
58. Patient preferences for treatment of multiple sclerosis with disease-modifying therapies: a discrete choice experiment.
Garcia-Dominguez JM; Muñoz D; Comellas M; Gonzalbo I; Lizán L; Polanco Sánchez C
Patient Prefer Adherence; 2016; 10():1945-1956. PubMed ID: 27713622
[TBL] [Abstract][Full Text] [Related]
59. Systematic literature review and network meta-analysis in highly active relapsing-remitting multiple sclerosis and rapidly evolving severe multiple sclerosis.
Huisman E; Papadimitropoulou K; Jarrett J; Bending M; Firth Z; Allen F; Adlard N
BMJ Open; 2017 Mar; 7(3):e013430. PubMed ID: 28283486
[TBL] [Abstract][Full Text] [Related]
60. Novel and imminently emerging treatments in relapsing-remitting multiple sclerosis.
Oh J; O'Connor PW
Curr Opin Neurol; 2015 Jun; 28(3):230-6. PubMed ID: 25887773
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
